DGAP-News: MorphoSys Concludes a US$ 100 Million Capital Increase to Implement the Purchase of 1,337,552 shares by Royalty Pharma
The new ordinary shares represent 3.9% of the registered share capital of MorphoSys following the capital increase.
- The new ordinary shares represent 3.9% of the registered share capital of MorphoSys following the capital increase.
- "We're pleased that Royalty Pharma is taking an equity position in MorphoSys as part of the long-term strategic finance partnership the two companies entered into this year," said Sung Lee, Chief Financial Officer of MorphoSys.
- The new MorphoSys shares will be listed on the Frankfurt Stock Exchange.
- Royalty Pharma has agreed, subject to limited exceptions, not to sell or otherwise transfer any of the new ordinary shares for a period of twelve months.